News Releases

Released : October 27, 2016 07:00   RNS Number : 5694N MaxCyte, Inc. 27 October 2016         MaxCyte, Inc. ("MaxCyte" or the "Company")   Result of Annual General Meeting   Maryland, USA - 27 October 2016: MaxCyte (LSE: MXCT), the revenue-generating developer of next generation cell-based
Oct 27, 2016
Released : October 21, 2016 07:43   RNS Number : 1438N MaxCyte, Inc. 21 October 2016         MaxCyte, Inc. ("MaxCyte" or the "Company")   Driector/PDMR Sharedealing   Maryland, USA - 21 October 2016: MaxCyte (LSE: MXCT), the revenue-generating developer of next generation cell-based medicines,
Oct 21, 2016
Released : September 28, 2016 18:00   RNS Number : 1371L MaxCyte, Inc. 28 September 2016         MaxCyte, Inc. ("MaxCyte" or the "Company")   Grant of Options   Gaithersburg, MD , 28 September 2016 - MaxCyte (LSE: MXCT) , an established and revenue generating US-based developer and supplier of cell
Sep 28, 2016
Released : September 27, 2016 07:00   RNS Number : 8786K MaxCyte, Inc. 27 September 2016       MaxCyte, Inc. ("MaxCyte" or the "Company")   Financial Results for the Six Months ended 30 June 2016   Maryland, USA - 27 September - MaxCyte, Inc. (LSE: MXCT) , an established and revenue generating
Sep 27, 2016
Released : September 19, 2016 17:00   RNS Number : 2422K MaxCyte, Inc. 19 September 2016         MaxCyte, Inc. ("MaxCyte" or the "Company")   Notification of Annual General Meeting   Maryland, USA - 19 September 2016: MaxCyte (LSE: MXCT), the developer and supplier of cell engineering technology to
Sep 19, 2016
Released : September 06, 2016 07:00   RNS Number : 0072J MaxCyte, Inc. 06 September 2016                 MaxCyte Bolsters Distributor Network in Asia to Meet Growing Market Demands for MaxCyte STX® and MaxCyte VLX® Transfection Systems   Gaithersburg, MD , 6 September 2016 - MaxCyte®, Inc., the
Sep 06, 2016
Released : September 06, 2016 07:00   RNS Number : 0077J MaxCyte, Inc. 06 September 2016         MaxCyte, Inc. ("MaxCyte" or the "Company")   Notice of Half Year Results   Maryland, USA - 06 September 2016: MaxCyte (LSE: MXCT), an established and revenue generating US-based developer and supplier
Sep 06, 2016